Mitochondrial disorders often present as multi-system conditions causing high morbidity and mortality. There are currently few therapy possibilities for mitochondrial diseases, which makes finding useful therapies aiming to treat mitochondrial dysfunction critically important. Protheragen's service of developing macromolecular therapeutics provides focused expertise in formulating therapy plans for mitochondrial diseases with macromolecular drugs.
Our Services
Through effective macromolecular drug development services, our goal is to provide a novel solution to treat mitochondrial dysfunction at its deepest level. Protheragen, through strategic collaborations and innovative research, aims to fast-track the translation of novel therapeutic candidates from a bench to preclinical testing.
Enzyme replacement therapy (ERT) involves introducing a therapeutic agent enzyme externally in individuals who have deficient or malfunctioning enzymes due to metabolic conditions. The current focus of our ERT development service is designing and optimizing macromolecular enzymes specific to the mitochondrial targets or pathways implicated in mitochondrial diseases. We aim, through recombinant protein expression, purification, and formulation, to develop ERT candidates with greater stability, efficacy, and tissue specificity for the therapy of mitochondrial diseases.
Therapeutic antibodies serve as a therapy option and also are highly effective in curing numerous ailments, including mitochondrial disorders. Using our fully integrated therapeutic development service, we can help you discover, design, and enhance specific monoclonal antibodies aimed at the important proteins or pathways within the mitochondria disease. With the help of sophisticated antibody engineering platforms, we seek to create novel therapeutic antibodies with improved affinity, specificity, and enhanced pharmacokinetics for aiding research directed toward the therapy of mitochondrial diseases.
Our Advantages
- Specialized Expertise
Our team of scientists is distinguished with specialization in macromolecular drug development and mitochondrial biology, which allows us to devise and execute highly innovative strategies to treat mitochondrial diseases.
- Customized Solutions
Offer customized solutions specifically to meet the distinct requirements and objectives of each client. Our services vary from developing enzyme replacement therapies to engineering therapeutic antibodies for the advancement of the therapy of mitochondrial diseases.
- Accelerated Development Timeline
Technology and workflows at our company are custom, which allows us to minimize the time spent on drug development. Our clients benefit from rapid progression through the entire drug development cycle. Our efficient experimental protocols ensure the timely delivery of high-quality data, facilitating informed decision-making throughout the entire development process.
Protheragen offers full and customized services for macromolecular drug development to further innovative therapy solutions for mitochondrial diseases. If you have inquiries regarding our service for macromolecular drug development for mitochondrial disease or are interested in possible collaborative ventures, do not hesitate to contact us.
